Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01432457 · ClinicalTrials.gov registry record · Phase 4
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
A Phase 4 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 924
- Enrollment target
NCT01432457: Completed Phase 4 study, sponsored by Pfizer.
NCT01432457 is a Phase 4 study that has completed, run by Pfizer. The registered enrollment target is 924 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (78% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01432457, a Phase 4 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 924 participants
- Enrollment target
Study Summary
A multicenter, 8-week study to evaluate the efficacy of 2 doses (50 and 100 mg/day) of desvenlafaxine succinate sustained-release (DVS SR) versus placebo in adult outpatients with major depressive disorder.
Primary Outcome
HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression (symptoms such as depressed mood, guilty feelings, suicide, sleep disturbances, anxiety levels, and weight loss). Each item is scored on either a 3 point (0 to 2) or a 5 point scale (0 to 4), for a maximum total score of 52; higher scores indicate more depression. Change from baseline: score at observation minus score at baseline.
Interventions
- DRUG placebo
- DRUG desvenlafaxine succinate sustained-release 50 mg/day
- DRUG desvenlafaxine succinate sustained-release 100 mg/day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 924 participants |
| Start Date | 2011-10 |
| Est. Completion | 2012-08 |
| Phase | Phase 4 |
What the finished NCT01432457 record still lists
NCT01432457 is an interventional study that assigns participants to a tested intervention. The registered 924 participants enrollment target is mid-sized for trials with a published cap, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (78% higher).
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT01432457 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01432457 about?
NCT01432457 is a clinical study titled "Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)". A multicenter, 8-week study to evaluate the efficacy of 2 doses (50 and 100 mg/day) of desvenlafaxine succinate sustained-release (DVS SR) versus placebo in adult outpatients with major depressive disorder.
What is the current status of trial NCT01432457?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 924 participants. The study started on 2011-10. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01432457?
The interventions under investigation include: placebo (DRUG), desvenlafaxine succinate sustained-release 50 mg/day (DRUG), desvenlafaxine succinate sustained-release 100 mg/day (DRUG).
Who is sponsoring clinical trial NCT01432457?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01432457's enrollment target sits among peer trials
924 81st of 2000 higher than 1,920 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04692493 · 924 participants · Phase 3
Ra-pro Pragmatic Trial
- NCT05656807 · 924 participants · NA
Evaluation of Child Care Staff Weight Management Program
- NCT06082453 · 924 participants · NA
Modernizing Perinatal Syphilis Testing
- NCT03995082 · 925 participants · NA
Breast Cancer Patient Engagement With Patient Reported Outcome Measure Survey
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia